The abstract is read at the publisher; the summary is JClub's.
A rare germline NELFE intronic variant, NM_002904.6:c.943-110C>T (rs79208225), promotes skipping of NELFE exon 10 and is linked to lower NELFE expression and longer recurrence-free survival in HCC patients.
- Why it matters: NELFE is oncogenic in hepatocellular carcinoma and lacks targeted therapies, so a naturally occurring, druggable splicing vulnerability could enable a localized treatment strategy.
- What they did: The study used mechanistic splice analysis showing reduced U2AF2 occupancy at intron 9, then designed morpholino antisense oligonucleotides against NELFE exon 10 splice junctions and tested them in HCC cell lines and orthotopic liver tumors with UTMD delivery.
- The result: Exon 10 splice switching lowered NELFE protein and impaired malignant phenotypes in vitro, and UTMD-delivered NELFE morpholinos reduced tumor burden and extended survival in orthotopic liver tumors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.